Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis

Review proposal consultation

Stakeholder matrix (PDF 40 KB)

Psoriatic arthritis - etanercept, infliximab and adalimumab: review proposal - June 2013 information

Psoriatic arthritis - etanercept, infliximab and adalimumab review proposal: Appendix A matrix of stakeholders

Psoriatic arthritis - etanercept, infliximab and adalimumab review proposal: Appendix A matrix of stakeholders (PDF 40 KB)

Psoriatic arthritis - etanercept, infliximab and adalimumab review proposal: Appendix B proposal paper presented to the Institute's Guidance Executive

Psoriatic arthritis - etanercept, infliximab and adalimumab review proposal: Appendix B proposal paper presented to the Institute's Guidance Executive (PDF 468 KB)

Psoriatic arthritis - etanercept, infliximab and adalimumab: press release information

Download a PDF version of this press release

Psoriatic arthritis - etanercept, infliximab, & adalimumab (review): final appraisal determination information

Psoriatic arthritis - etanercept, infliximab, & adalimumab (review): final appraisal determination

Psoriatic arthritis - etanercept, infliximab, & adalimumab (review): final appraisal determination (PDF 227 KB)

Psoriatic arthritis - etanercept, infliximab, & adalimumab (review): response to consultee, commentator and public comments on the ACD

Psoriatic arthritis - etanercept, infliximab, & adalimumab (review): response to consultee, commentator and public comments on the ACD (PDF 138 KB)

Consultee and commentator comments on the ACD

Abbott response to PsA ACD

Abbott response to PsA ACD (PDF 15 KB)

Pfizer Enbrel response to PsA ACD

Pfizer Enbrel response to PsA ACD (PDF 14 KB)

Pfizer Enbrel pooled estimates of PASI response

Pfizer Enbrel pooled estimates of PASI response (PDF 15 KB)

Schering Plough response to PsA ACD

Schering Plough response to PsA ACD (PDF 139 KB)

The Psoriasis and Psoriatic Arthritis Alliance response to PsA ACD

The Psoriasis and Psoriatic Arthritis Alliance response to PsA ACD (PDF 72 KB)

Royal College of Nursing response to PsA ACD

Royal College of Nursing response to PsA ACD (PDF 22 KB)

Department of Health response to PsA ACD

Department of Health response to PsA ACD (PDF 10 KB)

NHS Quality Improvement Scotland response to PsA ACD

NHS Quality Improvement Scotland response to PsA ACD (PDF 19 KB)

Welsh Assembly Government response to PsA ACD

Welsh Assembly Government response to PsA ACD (PDF 8.9 KB)

York Assessment Group response to PsA ACD

York Assessment Group response to PsA ACD (PDF 16 KB)

Expert comments on the ACD

Dr Eleanor Korendowych

Dr Eleanor Korendowych (PDF 8.2 KB)

Dr Philip Helliwell

Dr Philip Helliwell (PDF 8.2 KB)

Revisions to the cost effectiveness analysis after the committee meeting of 16 February 2010

Revisions to the cost effectiveness analysis after the committee meeting of 16 February 2010 (PDF 50 KB)

Revisions to the cost effectiveness analysis following comments from consultees on 2 February 2010

Psoriatic arthritis - etanercept, infliximab, & adalimumab (review): appraisal consultation document

Psoriatic arthritis - etanercept, infliximab, & adalimumab (review): appraisal consultation document information

Psoriatic arthritis - etanercept, infliximab, & adalimumab (review) ACD: evaluation report

Psoriatic arthritis - etanercept, infliximab, & adalimumab (review) ACD: overview

Psoriatic arthritis - etanercept, infliximab, & adalimumab (review) ACD: overview (PDF 257 KB)

Psoriatic arthritis - etanercept, infliximab, & adalimumab (review) ACD: assessment report

Psoriatic arthritis - etanercept, infliximab, & adalimumab (review) ACD: assessment report

Psoriatic arthritis - etanercept, infliximab, & adalimumab (review) ACD: assessment report (PDF 2.65 MB)

Psoriatic arthritis - etanercept, infliximab, & adalimumab (review) ACD: additional analyses following committee meeting

Psoriatic arthritis - etanercept, infliximab, & adalimumab (review) ACD: additional analyses following committee meeting (PDF 26 KB)

Psoriatic arthritis - etanercept, infliximab, & adalimumab (review) ACD: appendix 10.13

Psoriatic arthritis - etanercept, infliximab, & adalimumab (review) ACD: appendix 10.13 (PDF 46 KB)

Psoriatic arthritis - etanercept, infliximab, & adalimumab (review) ACD: responses to consultees' comments

Psoriatic arthritis - etanercept, infliximab, & adalimumab (review) ACD: responses to consultees' comments (PDF 150 KB)

Psoriatic arthritis - etanercept, infliximab, & adalimumab (review) ACD: consultee and commentator comments on the assessment report

Psoriatic arthritis - etanercept, infliximab, & adalimumab (review) ACD: consultee and commentator comments on the assessment report - Abbott AR

Psoriatic arthritis - etanercept, infliximab, & adalimumab (review) ACD: consultee and commentator comments on the assessment report - Abbott AR (PDF 188 KB)

Psoriatic arthritis - etanercept, infliximab, & adalimumab (review) ACD: consultee and commentator comments on the assessment report - Abbott EM

Psoriatic arthritis - etanercept, infliximab, & adalimumab (review) ACD: consultee and commentator comments on the assessment report - Abbott EM (PDF 31 KB)

Psoriatic arthritis - etanercept, infliximab, & adalimumab (review) ACD: consultee and commentator comments on the assessment report - British Association of Dermatologists

Psoriatic arthritis - etanercept, infliximab, & adalimumab (review) ACD: consultee and commentator comments on the assessment report - British Association of Dermatologists (PDF 8.9 KB)

Psoriatic arthritis - etanercept, infliximab, & adalimumab (review) ACD: consultee and commentator comments on the assessment report - British Society for Rheumatology

Psoriatic arthritis - etanercept, infliximab, & adalimumab (review) ACD: consultee and commentator comments on the assessment report - British Society for Rheumatology (PDF 94 KB)

Psoriatic arthritis - etanercept, infliximab, & adalimumab (review) ACD: consultee and commentator comments on the assessment report - Hull Teaching PCT

Psoriatic arthritis - etanercept, infliximab, & adalimumab (review) ACD: consultee and commentator comments on the assessment report - Hull Teaching PCT (PDF 34 KB)

Psoriatic arthritis - etanercept, infliximab, & adalimumab (review) ACD: consultee and commentator comments on the assessment report - Schering Plough

Psoriatic arthritis - etanercept, infliximab, & adalimumab (review) ACD: consultee and commentator comments on the assessment report - Schering Plough (PDF 185 KB)

Psoriatic arthritis - etanercept, infliximab, & adalimumab (review) ACD: consultee and commentator comments on the assessment report - Welsh Assembly Government

Psoriatic arthritis - etanercept, infliximab, & adalimumab (review) ACD: consultee and commentator comments on the assessment report - Welsh Assembly Government (PDF 7.7 KB)

Psoriatic arthritis - etanercept, infliximab, & adalimumab (review) ACD: consultee and commentator comments on the assessment report - Wyeth

Psoriatic arthritis - etanercept, infliximab, & adalimumab (review) ACD: consultee and commentator comments on the assessment report - Wyeth (PDF 26 KB)

Psoriatic arthritis - etanercept, infliximab, & adalimumab (review) ACD: non-manufacturer submission

Psoriatic arthritis - etanercept, infliximab, & adalimumab (review) ACD: non-manufacturer submission - Royal College of Physicians

Psoriatic arthritis - etanercept, infliximab, & adalimumab (review) ACD: non-manufacturer submission - Royal College of Physicians (PDF 7.8 KB)

Psoriatic arthritis - etanercept, infliximab, & adalimumab (review) ACD: non-manufacturer submission - British Society for Rheumatology

Psoriatic arthritis - etanercept, infliximab, & adalimumab (review) ACD: non-manufacturer submission - British Society for Rheumatology (PDF 87 KB)

Psoriatic arthritis - etanercept, infliximab, & adalimumab (review) ACD: non-manufacturer submission - British Association of Dermatologists

Psoriatic arthritis - etanercept, infliximab, & adalimumab (review) ACD: non-manufacturer submission - British Association of Dermatologists (PDF 24 KB)

Psoriatic arthritis - etanercept, infliximab, & adalimumab (review) ACD: manufacturer submissions

Psoriatic arthritis - etanercept, infliximab, & adalimumab (review) ACD: manufacturer submissions - Abbott

Psoriatic arthritis - etanercept, infliximab, & adalimumab (review) ACD: manufacturer submissions - Abbott (PDF 34 KB)

Psoriatic arthritis - etanercept, infliximab, & adalimumab (review) ACD: manufacturer submissions - Schering Plough

Psoriatic arthritis - etanercept, infliximab, & adalimumab (review) ACD: manufacturer submissions - Schering Plough (PDF 40 KB)

Psoriatic arthritis - etanercept, infliximab, & adalimumab (review) ACD: manufacturer submissions - Wyeth

Psoriatic arthritis - etanercept, infliximab, & adalimumab (review) ACD: manufacturer submissions - Wyeth (PDF 130 KB)

Psoriatic arthritis - etanercept, infliximab, & adalimumab (review) ACD: expert written personal statements

Psoriatic arthritis - etanercept, infliximab, & adalimumab (review) ACD: expert written personal statements - Helliwell

Psoriatic arthritis - etanercept, infliximab, & adalimumab (review) ACD: expert written personal statements - Helliwell (PDF 32 KB)

Psoriatic arthritis - etanercept, infliximab, & adalimumab (review) ACD: expert written personal statements - Korendowych

Psoriatic arthritis - etanercept, infliximab, & adalimumab (review) ACD: expert written personal statements - Korendowych (PDF 22 KB)

Psoriatic arthritis - etanercept, infliximab, & adalimumab (review) ACD: expert written personal statements - Morris

Psoriatic arthritis - etanercept, infliximab and adalimumab: Final Assessment Report

Psoriatic arthritis - etanercept, infliximab, & adalimumab (review): final protocol

Psoriatic arthritis - etanercept, infliximab and adalimumab (review): Consultee and commentator comments on the draft scope, and the Institute's response

Psoriatic arthritis - etanercept, infliximab, golimumab and adalimumab (review): Final matrix of consultees and commentators

Psoriatic arthritis - etanercept, infliximab, golimumab and adalimumab (review): final scope

Psoriatic arthritis - etanercept, infliximab, golimumab and adalimumab (review): draft scope

Psoriatic arthritis - etanercept, infliximab, golimumab and adalimumab (review): provisional matrix of consultees and commentators

Psoriatic arthritis - etanercept, infliximab and adalimumab (review): update on scope 

Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis (review): draft scope

Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis (review): provisional matrix